Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

NCT01968733 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

863

Enrollment

INDUSTRY

Sponsor class

Conditions

Community-acquired Bacterial Pneumonia

Interventions

DRUG: Solithromycin
DRUG: Moxifloxacin

Sponsor

Melinta Therapeutics, Inc.